TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17329091

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: General Exercise Reconditioning (GER) + IMT
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham IMT
Number of subjects: 34
Study: 15452803

Group type: EXPERIMENTAL
Intervention: Tongue reduction surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no tongue reduction)
Number of subjects: 40
Study: 12194637

Group type: EXPERIMENTAL
Intervention: Educational group (25 patients)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care group (27 patients)
Number of subjects: 52
Study: 9498258

Group type: EXPERIMENTAL
Intervention: Phenprocoumon for 3 months (n = 47)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 90)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Ticlopidine 2 x 250 mg/d and low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 72)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Ticlopidine 2 x 250 mg/d for 4 weeks (n = 125)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (phenprocoumon and low molecular weight heparin)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Phenprocoumon and low molecular weight heparin
Number of subjects: 334
Study: 7623360

Group type: EXPERIMENTAL
Intervention: Manchester procedure (MP)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 193
Study: 2695866

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive containing cyproterone acetate
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Other low-dose oral contraceptives (desogestrel, gestodene)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 340141

Group type: EXPERIMENTAL
Intervention: Pentazocine (15 mg) plus Paracetamol (500 mg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Dextropropoxyphene hydrochloride (32.5 mg) plus Paracetamol (325 mg)
Number of subjects: 167
Study: 7361103

Group type: EXPERIMENTAL
Intervention: Blend of seven artificial colors
Number of subjects: 22
Study: 31743571

Group type: EXPERIMENTAL
Intervention: Nano hydroxyapatite bone substitute
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tent group (graftless tenting technique)
Number of subjects: 20
Study: 28678345

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain ≥7% weight loss
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education intervention (DSE)
Number of subjects: 5145
Study: 26373822

Group type: EXPERIMENTAL
Intervention: Acute exercise (40-min single bout) in PCOS group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Acute exercise (40-min single bout) in CTRL group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Acute exercise (40-min single bout) in both PCOS and CTRL groups
Number of subjects: 27
Study: 23678117

Group type: EXPERIMENTAL
Intervention: Cholinergic transients observed during signal-hit trials (incongruent hits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent hits activating right rostral PFC (Brodmann area 10)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of tissue oxygen as a proxy for BOLD in rats
Number of subjects: 0
Study: 21488750

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18-54 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 19773644

Group type: EXPERIMENTAL
Intervention: Creatine ethyl ester supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17689968

Group type: EXPERIMENTAL
Intervention: Vancomycin (VAN) 15 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Teicoplanin (TEC) 8 mg/kg
Number of subjects: 22
Study: 15071872

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (ICB) using 0.25% bupivacaine before operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with chest tube insertion (Group CT)
Number of subjects: 30
Study: 11860326

Group type: EXPERIMENTAL
Intervention: TBI survivors
Number of subjects: 23

Group type: COMPARATOR
Intervention: Young adults without neurological impairment
Number of subjects: 23
Study: 10643541

Group type: EXPERIMENTAL
Intervention: EPOCH regimen (etoposide 50 mg/m2, vincristine 0.4 mg/m2, doxorubicin 10 mg/m2 continuous infusion days 1-4; cyclophosphamide 750 mg/m2 i.v. bolus day 6; prednisone 60 mg/m2 days 1-6)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CHOP regimen (as routinely prescribed)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: EPOCH regimen
Number of subjects: 78

Group type: COMPARATOR
Intervention: CHOP regimen
Number of subjects: 78
Study: 7605854

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg p.o. daily
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg p.o. daily
Number of subjects: 229

Group type: COMPARATOR
Intervention: Ranitidine 150 mg p.o. b.d.
Number of subjects: 229
Study: 2132340

Group type: EXPERIMENTAL
Intervention: Dual oximetry using Edwards catheter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dual oximetry using Spectramed catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transition from two-lung ventilation (2LV) to one-lung ventilation (1LV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous oximetry
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monitoring SvO2
Number of subjects: 30
Study: 734581

Group type: EXPERIMENTAL
Intervention: Left lateral tilt
Number of subjects: 75

Group type: COMPARATOR
Intervention: Right lateral tilt
Number of subjects: 75
Study: 30902094

Group type: EXPERIMENTAL
Intervention: Daily electronic patient-reported outcome (PRO) diary
Number of subjects: 1989
Study: 27872058

Group type: EXPERIMENTAL
Intervention: Lestaurtinib (CEP701)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control (no lestaurtinib)
Number of subjects: 500
Study: 24919961

Group type: EXPERIMENTAL
Intervention: VIPP-AUTI
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 23478059

Group type: EXPERIMENTAL
Intervention: Abagovomab 2 mg administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Number of subjects: 888

Group type: COMPARATOR
Intervention: Placebo administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Abagovomab
Number of subjects: 888
Study: 21777052

Group type: EXPERIMENTAL
Intervention: Heat acclimation (10 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pre-cooling (20 min with ice packs)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control conditions (no pre-cooling)
Number of subjects: 8
Study: 19210857

Group type: EXPERIMENTAL
Intervention: Oily fish diet (four portions per week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Red meat diet (four portions per week)
Number of subjects: 25
Study: 16458970

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's capsule injection of 20 mg triamcinolone acetonide (TA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control eye (no TA injection)
Number of subjects: 10
Study: 15255456

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Propafenone (recent onset AF with spontaneous conversion)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (recent onset AF with spontaneous conversion)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Propafenone (persistent AF)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (persistent AF)
Number of subjects: 110
Study: 11966483

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg, 4 times at 4 hour intervals)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin infusion (starting at 1 mIU/min, increasing every 30 minutes up to 30 mIU/min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 100
Study: 9809179

Group type: EXPERIMENTAL
Intervention: Concentric training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of both concentric and eccentric training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 28
Study: 7897876

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 40
Study: 2676911

Group type: EXPERIMENTAL
Intervention: Combination therapy of 18,000 IE retinol, 70 mg L‐cystine, and 7000 mg gelatin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 365487

Group type: EXPERIMENTAL
Intervention: Amikacin (375 mg/d three times i.m.)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Gentamicin (80 mg/d three times i.m.)
Number of subjects: 25
Study: 31678988

Group type: EXPERIMENTAL
Intervention: Physical activity and nutritional advice (Intervention Group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Theoretical-practical sessions on nutrition (Control Group)
Number of subjects: 98
Study: 30114561

Group type: EXPERIMENTAL
Intervention: Tinzaparin (4500 IU daily until 37 gestational weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No tinzaparin (control group)
Number of subjects: 53
Study: 27176661

Group type: EXPERIMENTAL
Intervention: CHOICES (information plus counseling; IPC)
Number of subjects: 830

Group type: COMPARATOR
Intervention: Information only (IO)
Number of subjects: 830
Study: 25197922

Group type: EXPERIMENTAL
Intervention: Nebulized 9-mg sodium hyaluronate nasal washes plus saline solution
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline alone (5 mL)
Number of subjects: 39
Study: 22276958

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 890
Study: 20093905

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n=59)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 109
Study: 17396441

Group type: EXPERIMENTAL
Intervention: 5 MU/m2 IFN-alpha therapy for 6 months
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 10 MU/m2 IFN-alpha therapy for 6 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 68
Study: 15618257

Group type: EXPERIMENTAL
Intervention: Medical abortion (600 mg mifepristone followed by 1 mg gemeprost)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Surgical abortion (vacuum aspiration in general anaesthesia)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Failed medical abortion
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Failed surgical abortion
Number of subjects: 1033
Study: 11860971

Group type: EXPERIMENTAL
Intervention: Prophylactic laser therapy (16 eyes)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment (19 eyes)
Number of subjects: 29
Study: 10624637

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 36
Study: 7728784

Group type: EXPERIMENTAL
Intervention: Physicians' judgment on a 1-5 scale (1 = no suspicion; 5 = convinced) regarding AMI suspicion before interpreting ECG.
Number of subjects: 0
Study: 2028775

Group type: EXPERIMENTAL
Intervention: Tear meniscus cytology
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conjunctival fluid cytology
Number of subjects: 200
Study: 6112842

Group type: EXPERIMENTAL
Intervention: Active antiparkinson (AP) medication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31168590

Group type: EXPERIMENTAL
Intervention: Bovine Colostrum (BC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 30716938

Group type: EXPERIMENTAL
Intervention: Strawberries grown on biodegradable mulch
Number of subjects: 1510

Group type: EXPERIMENTAL
Intervention: Information treatment on biodegradable mulches
Number of subjects: 1510

Group type: EXPERIMENTAL
Intervention: Demographic factors (female, higher income, stronger environment-friendly attitudes)
Number of subjects: 1510
Study: 28944357

Group type: EXPERIMENTAL
Intervention: Endodontic retreatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Implant-supported crown
Number of subjects: 40
Study: 26755507

Group type: EXPERIMENTAL
Intervention: Volasertib 300 mg by intravenous infusion every 3 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of single-agent, nonplatinum, cytotoxic chemotherapy)
Number of subjects: 109
Study: 23511382

Group type: EXPERIMENTAL
Intervention: Threatening information
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nonthreatening information
Number of subjects: 63
Study: 22521755

Group type: EXPERIMENTAL
Intervention: Leaflet group (n = 42)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: One-to-one group (n = 46)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 112
Study: 19643483

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%
Number of subjects: 1161
Study: 17957450

Group type: EXPERIMENTAL
Intervention: Reports of a work compensation claim within the year previous to baseline (females)
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: High level of health anxiety (females)
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: One or more contacts to the general practitioner in the year previous to baseline (females)
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Reported poor leadership quality at work (females)
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: High levels of health anxiety (males)
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Repetitive work (males)
Number of subjects: 5604
Study: 15751665

Group type: EXPERIMENTAL
Intervention: Heparin during CPB in patients with postoperative SIRS (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group A (normal postoperative course)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inflammatory parameters in SIRS group
Number of subjects: 32
Study: 12061965

Group type: EXPERIMENTAL
Intervention: Two-handed lifting with two feet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One-handed supported lifting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lifting from the upper front region of the bin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bin design with a hand hold
Number of subjects: 24
Study: 9858352

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin 2.4 million units intramuscularly once
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin plus amoxicillin 2 g and probenecid 500 mg orally three times daily for 10 days
Number of subjects: 525
Study: 7878752

Group type: EXPERIMENTAL
Intervention: Urine flow immunocytometry (UFC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urine cytology (UC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined use of UC and UFC
Number of subjects: 40
Study: 1454956

Group type: EXPERIMENTAL
Intervention: Experimental Group (exposed to a distinctive stimulus before each infusion of chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 6230999

Group type: EXPERIMENTAL
Intervention: Topical 1.5% erythromycin solution
Number of subjects: 154

Group type: COMPARATOR
Intervention: Topical 1% clindamycin phosphate solution
Number of subjects: 154
Study: 30759445

Group type: EXPERIMENTAL
Intervention: TEM-CAP
Number of subjects: 247

Group type: COMPARATOR
Intervention: 5FU-DTIC
Number of subjects: 247
Study: 30077032

Group type: EXPERIMENTAL
Intervention: Kyphoplasty (KP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vertebroplasty (VP)
Number of subjects: 46
Study: 26715213

Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg (EFV400)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Efavirenz 600 mg (EFV600)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: CYP2B6 983TC/CC genotype
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: CYP2B6 15582CT/TT and ABCB1 3435TT genotypes
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: C12 between 0.47 and 0.76 mg/L
Number of subjects: 606
Study: 25637886

Group type: EXPERIMENTAL
Intervention: Gaining abstinence (defined as achieving seven-day point prevalent abstinence at any post-initial abstinence assessment)
Number of subjects: 287
Study: 23609378

Group type: EXPERIMENTAL
Intervention: Typical antipsychotics (TAs)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 308

Group type: COMPARATOR
Intervention: Nonclozapine atypical antipsychotics (AAs)
Number of subjects: 308
Study: 21045576

Group type: EXPERIMENTAL
Intervention: Internet-based education intervention
Number of subjects: 0
Study: 18235202

Group type: EXPERIMENTAL
Intervention: Ganciclovir 50 mg/ml
Number of subjects: 29

Group type: COMPARATOR
Intervention: NaCl 9% (placebo)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 17000819

Group type: EXPERIMENTAL
Intervention: Standard intraoperative and postoperative analgesic regimen (morphine sulfate, diclofenac, dextropropoxyphene hydrochloride + acetaminophen prn)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Continuous paravertebral block (for 48 h) and acetaminophen and parecoxib (followed by celecoxib up to 5 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patients with a pain rating index = 0 (n = 11)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Patients with a pain rating index > or =1 (n = 18)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Group N (continuous paravertebral block)
Number of subjects: 29
Study: 14582587

Group type: EXPERIMENTAL
Intervention: Brief information + occlusal appliance (BI + OA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Brief information + relaxation therapy (BI + RT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Brief information (BI)
Number of subjects: 122
Study: 11053174

Group type: EXPERIMENTAL
Intervention: Community based intervention (n=72)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Hospital based intervention (n=69)
Number of subjects: 141
Study: 9117183

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate (MTX)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral methotrexate (MTX)
Number of subjects: 21
Study: 8449126

Group type: EXPERIMENTAL
Intervention: Physiologic concentration of SCFAs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Total SCFA concentration after IPAA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Stool frequency
Number of subjects: 14
Study: 2887188

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31601123

Group type: EXPERIMENTAL
Intervention: Multidisciplinary parent training program (Poly Kids)
Number of subjects: 218
Study: 29277358

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided manual lymph drainage (MLD)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Traditional 'blind' MLD
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo MLD
Number of subjects: 201
Study: 27340112

Group type: EXPERIMENTAL
Intervention: Escitalopram + internet-delivered cognitive-behavioural therapy (ICBT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Escitalopram + ICBT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo + ICBT
Number of subjects: 48
Study: 23989498

Group type: EXPERIMENTAL
Intervention: Multimodal aerobic and strength exercises (TG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard physiotherapy (CG)
Number of subjects: 48
Study: 23173250

Group type: EXPERIMENTAL
Intervention: Rhubarb + Pantoprazole
Number of subjects: 107

Group type: COMPARATOR
Intervention: Pantoprazole
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (AMI patients without HF)
Number of subjects: 107
Study: 20595543

Group type: EXPERIMENTAL
Intervention: β1‐adrenoreceptor blocker (atenolol; βB) 0.2 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo control (PL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hyperthermia-PL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Normothermia-βB
Number of subjects: 11
Study: 18046056

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15651559

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with insulin lispro
Number of subjects: 7
Study: 12402765

Group type: EXPERIMENTAL
Intervention: Avelox (400 mg/day for 10 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg twice a day for 10 days)
Number of subjects: 63
Study: 7995328

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine and Saline
Number of subjects: 0
Study: 2980291

Group type: EXPERIMENTAL
Intervention: CR-capsules (controlled release)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Unixan tablets
Number of subjects: 11
Study: 31838407

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 in early breast cancer (EBC)
Number of subjects: 5521

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 in metastatic breast cancer (MBC)
Number of subjects: 5521

Group type: EXPERIMENTAL
Intervention: Presence of poor performance status (PS) and comorbidities in MBC
Number of subjects: 5521

Group type: COMPARATOR
Intervention: Comparison of HRQoL scores across age and countries
Number of subjects: 5521